Abstract
A model comprised of four compartments, a central and liver compartment for a drug, and a central and liver compartment for a metabolite, is presented to describe the interrelationships between the area under the curve of the metabolite and physiological parameters after intravenous and intraportal administration of the drug. The model includes renal and hepatic eliminatory mechanisms for both drug and metabolite as long as the metabolite is formed only by the liver. It is found that when competing renal eliminatory pathways exist for a drug, the area under the curve for the metabolite will change according to the route of drug administration. Also, the fractional rate of metabolism of a drug to form the metabolite will be underestimated by the normal use of the ratio areas under the curve of the metabolite. Other properties of the model are also discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A. J. Cummings, B. K. Martin, and G. S. Park. Kinetic considerations relating to the accrual and elimination of drug metabolites.Br. J. Pharmacol. Chemother. 29:136–149 (1967).
M. Rowland and S. Riegelman. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man.J. Pharm. Sci. 57:1313–1319 (1968).
M. Rowland, L. Z. Benet, and S. Riegelman. Two-compartment model for a drug and its metabolite: application to acetylsalicylic acid pharmacokinetics.J. Pharm. Sci. 59:364–367 (1970).
S. A. Kaplan, M. L. Jack, S. Cotler, and K. Alexander. Utilization of area under the curve to elucidate the disposition of an extensively biotransformed drug.J. Pharmacokin. Biopharm. 1:201–216 (1973).
S. A. Kaplan, M. Lewis, M. A. Schwartz, E. Postema, S. Cotler, C. W. Abruzzo, T. L. Lee, and R. E. Weinfield. Pharmacokinetic model for chlordiazepoxide HCl in the dog.J. Pharm. Sci. 59:1549–1574 (1970).
H. G. Boxenbaum and S. Riegelman. Pharmacokinetics of isoniazid and some metabolites in man.J. Pharmacokin. Biopharm. 4:287–324 (1976).
I. H. Patel, R. H. Levy, and W. F. Trager. Pharmacokinetics of carbamazepine-10,11-epoxide before and after autoinduction in Rhesus monkeys.J. Pharmacol. Exp. Ther. 206:607–613 (1978).
J. Cobby, M. Mayersohn, and Selliah. Disposition kinetics in dogs of diethyldithiocarbamate, a metabolite of disulfiram.J. Pharmacokin. Biopharm. 6:368–387 (1978).
K. S. Pang and J. R. Gillette. Sequential first-pass elimination of a metabolite derived from a precursor.J. Pharmacokin. Biopharm. 7:275–290 (1979).
K. S. Pang, K. Strobl, and J. R. Gillette. A method for the estimation of the fraction of a precursor that is converted to a metabolite in ratin vivo with phenacetin and acetaminophen.Drug Metab. Dispos. 7:366–372 (1979).
K. S. Pang and J. R. Gillette. A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and hepatic blood flow.J. Pharmacokin. Biopharm. 6:355–367 (1978).
K. S. Pang and M. Rowland. Hepatic clearance of drugs. III. Additional experimental evidence supporting the “well-stirred” model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liverin situ preparation.J. Pharmacokin. Biopharm. 5:681–699 (1977).
K. S. Pang and J. R. Gillette. Metabolite pharmacokinetics: Methods for simultaneous estimates of elimination rate constants of a drug and its metabolite. A Commentary.Drug. Metab. Dispos. 8:39–43 (1980).
E. A. Lane and R. H. Levy. Prediction of steady-state behavior of metabolite from dosing of parent drug.J. Pharm. Sci. 69:610–612 (1980).
Author information
Authors and Affiliations
Additional information
This work is supported by a PHS grant (GM # 27323).
Rights and permissions
About this article
Cite this article
Pang, K.S. Metabolite pharmacokinetics: The area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolites. Journal of Pharmacokinetics and Biopharmaceutics 9, 477–487 (1981). https://doi.org/10.1007/BF01060890
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01060890